- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT00986440
Study of CS-7017 in Colorectal Cancer Patients Who Have Achieved Disease Control Following First-Line Chemotherapy
3 november 2020 bijgewerkt door: Daiichi Sankyo, Inc.
A Randomized, Double-Blind Placebo-Controlled Phase 2 Study of CS-7017 in Colorectal Cancer Patients Who Have Achieved Disease Control Following First-Line Chemotherapy
Monotherapy treatment with CS-7017 to assess progression-free-survival (PFS) of subjects who achieved an objective response of Disease Control on first line therapy with Folinic acid (leucovorin), Fluorouracil (5-FU), Oxaliplatin (Eloxatin) known as FOLFOX; or Folinic acid (leucovorin), Fluorouracil (5-FU), irinotecan (Camptosar) known as FOLFIRI.
Studie Overzicht
Toestand
Beëindigd
Conditie
Interventie / Behandeling
Studietype
Ingrijpend
Inschrijving (Werkelijk)
84
Fase
- Fase 2
Contacten en locaties
In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.
Studie Locaties
-
-
-
Donauwörth, Duitsland, 86609
- Onkologische Praxis Donauwörth
-
Halle, Duitsland, 06120
- Universitätsklinikum Halle Klinik und Poliklinik für Innere Medizin
-
München, Duitsland, 81675
- Klinikum rechts der Isar
-
-
-
-
-
Saint Grégoire, Frankrijk, 35768
- Centre Hospitalier Privé Saint Grégoire
-
-
Cedex
-
Colmar, Cedex, Frankrijk, 68024
- Hôpitaux civils de Colmar
-
Lyon, Cedex, Frankrijk, 69437
- Hôpital Edouard Herriot
-
Rennes, Cedex, Frankrijk, 35042
- Service d'Oncologie Médicale
-
-
-
-
-
Genova, Italië
- Ospedale San Martino
-
Lecce, Italië
- Unita Operativa di Oncologia Medica
-
Siena, Italië, 53100
- Policlinico Santa Maria alle Scotte
-
Udine, Italië, 33100
- Azienda Ospedaliero Universitaria Santa Maria della Misericordia
-
-
Torino
-
Candiolo, Torino, Italië, 10060
- Institute for Cancer Research and Treatment - IRCC
-
-
-
-
-
Kiev, Oekraïne, 03115
- Kyiv City Oncology Hospital
-
Sumy, Oekraïne, 40005
- Sumy Regional Oncology Center
-
-
Volyn
-
Lutsk, Volyn, Oekraïne
- Volyn Regional Oncology Dispensary
-
-
-
-
-
Bialystok, Polen, 15-027
- Bialostockie Centrum Onkologii im. Marii Sklodowskiej-Curie w Bialymstoku
-
Bytom, Polen, 41-902
- Wojewodzki Szpital Specjalistyczny
-
Gliwice, Polen, 44-101
- Centrum Onkologii Instytut im. Marii Sklodowskiej-Curie
-
Krakow, Polen, 31-108
- VESALIUS Sp. z o.o.
-
Warszawa, Polen, 01-002
- NZOZ ONKOLOG s.c.
-
-
-
-
-
Moscow, Russische Federatie, 125367
- Central Clinical Hospital #1
-
Moscow, Russische Federatie, 115478
- Russian Oncology Research Centre n.a. Blokhin, RAMS
-
Moscow, Russische Federatie, 129128
- NUZ Semashko Central Clinical Hospital
-
St Petersburg, Russische Federatie, 198255
- St-Petersburg State Institution of Public Health
-
St-Petersburg, Russische Federatie, 194291
- Federal State Institution of Healthcare Clinical Hospital # 122 n.a.L.G Sokolov
-
Tula, Russische Federatie, 300053
- Tula Regional Oncology Dispensary
-
-
Kaluga
-
Obninsk, Kaluga, Russische Federatie, 249030
- Medical Radiological Research Centre
-
-
Tatarstan
-
Kazan, Tatarstan, Russische Federatie, 4200111
- Kazan State Medical University
-
-
-
-
-
Pamplona, Spanje, 31008
- Clinica Universitaria de Navarra
-
Terrassa (Barcelona), Spanje, 08221
- Hospital Mútua de Terrassa
-
-
Villaroel
-
Barcelona, Villaroel, Spanje, 170
- H.Clinic I Provincial de Barcelona
-
-
-
-
-
Brno, Tsjechië, 62500
- Fakulti nemocnice Brno
-
Olomouc, Tsjechië, 77520
- Fakultni Nemocnice Olomouc
-
Znojmo, Tsjechië, 66902
- Nemocnice Znojmo, p.o., Oddeleni radiacni a klinicke onkologie
-
-
-
-
-
Aberdeen, Verenigd Koninkrijk, AB25 2ZN
- Aberdeen Royal Infirmary
-
London, Verenigd Koninkrijk, EC1A 7BE
- St.Bartholomew's Hospital
-
London, Verenigd Koninkrijk, NW1 2PQ
- UCLH Cancer Clinical Trials Unit
-
Manchester, Verenigd Koninkrijk, M20 4BX
- Christie Hospital
-
-
Middlesex
-
Northwood, Middlesex, Verenigd Koninkrijk, HA6 2RN
- Mount Vernon Cancer Centre
-
-
Deelname Criteria
Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
18 jaar en ouder (Volwassen, Oudere volwassene)
Accepteert gezonde vrijwilligers
Nee
Geslachten die in aanmerking komen voor studie
Allemaal
Beschrijving
Inclusion Criteria:
- Patients with histologically confirmed, metastatic CRC that have achieved confirmed maximal benefit of DC following treatment with standard first line chemotherapy of a 5-fluoropyrimidine plus either oxaliplatin or irinotecan. Patients should be entered onto this trial within 8 weeks of completing first line therapy;
- If CR was not achieved: measurable disease, i.e. at minimum one unidimensionally-measurable target lesion according to RECIST (Response Evaluation Criteria in Solid Tumors);
- Age >= 18 years and Eastern Cooperative Oncology Group (ECOG) performance status (PS) =< 2 at study entry;
- Resolution of any toxic effects of prior therapy (except alopecia) to NCI CTCAE, Version 3.0, grade =< 1;
Adequate organ and bone marrow function as evidenced by:
- Haemoglobin >= 10 g/dL (transfusion and/or growth factor support allowed);
- Absolute neutrophil count (ANC) >= 1.5 x 109/L;
- Platelet count >= 100 x 109/L;
- Serum creatinine =< 1.5 x ULN or creatinine clearance >60 mL/min;
- AST and alkaline phosphatase <2.5 x ULN if without liver metastasis and =< 5.0 x ULN if liver metastasis;
- Total bilirubin =< 2.0 x ULN;
- Prothrombin time (PT)/International Normalised Ratio (INR) within normal limits (WNL) unless therapeutically anticoagulated;
- Women of childbearing potential and men must be willing to consent to using highly effective methods of contraception (eg, hormonal contraceptives, bilateral tubal ligation, barrier with spermicide, intrauterine device) while on treatment and for at least 3 months thereafter;
- Males with the potential to father children must use two of the following methods of contraception acceptable for the study (e.g. hormonal contraceptives, bilateral tubal ligation, barrier with spermicide, intrauterine device) while on trial treatment and for at least 3 months thereafter.
- All female subjects of childbearing potential must have a negative pregnancy test (plasma or urine) result within 7 days before initiating study treatment;
- Baseline laboratory tests and tumor assessments must have been performed within 2 weeks before initiating study treatment;
- Subjects must be fully informed about their illness and the investigational nature of the study protocol (including foreseeable risks and possible side effects) and must sign and date an IEC-approved ICF before performance of any study specific procedures or tests.
Exclusion Criteria:
- Anticipation of need for a major surgical procedure or RT during the study;
- Treatment with chemotherapy, hormonal therapy, minor surgery, or any investigational agent within 4 weeks before study enrolment. Treatment with immunotherapy, biological therapy, or major surgery within 6 weeks before study enrolment. Treatment with RT within 1 week before study enrolment.
- History of any of the following conditions: diabetes mellitus requiring treatment with insulin or oral agents;
- Concomitant use of other TZDs;
- Myocardial infarction with significant impairment of cardiac function (e.g., ejection fraction =< 50%); severe/unstable angina pectoris; coronary/peripheral artery bypass graft; congestive heart failure; cerebrovascular accident (CVA) or transient ischemic attack (TIA), pulmonary embolism, or other clinically significant thromboembolic event; clinically significant pulmonary disease (e.g., severe chronic obstructive pulmonary disease [COPD] or asthma);
- Brain metastasis; an uncontrolled seizure disorder; spinal cord compression; or carcinomatous meningitis;
- Pleural or pericardial effusion. Subjects with minimal pleural effusion may be eligible upon request by Investigator and approval by Sponsor;
- Clinically significant active infection that requires antibiotic therapy or Human Immunodeficiency Virus (HIV) positive subjects receiving antiretroviral therapy;
- Pregnant or breast feeding;
- Known history of severe hypersensitivity reactions to any of the components of CS 7017 formulations;
- Serious intercurrent medical or psychiatric illnesses or any other conditions that in the opinion of the Investigator would impair the ability to give informed consent or unacceptably reduce protocol compliance or safety of the study treatment;
Studie plan
Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Verdrievoudigen
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: CS-7017
|
CS-7017
|
|
Placebo-vergelijker: Placebo
Placebo matching CS-7017
|
Placebo
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Percentage Rate of Progression-free Survival at 18 Weeks Following Use of CS-7017 in Colorectal Cancer Participants Who Have Achieved Disease Control Following First-Line Chemotherapy
Tijdsspanne: 18 weeks postdose
|
Progression-free survival (PFS) was defined as the time from enrollment to the date of the first objective documentation of disease progression or death resulting from any cause, whichever comes first.
Progression was defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) as at least a 20% increase in the sum of diameters of target lesions.
|
18 weeks postdose
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Percentage Rate of Progression-free Survival Following Use of CS-7017 in Colorectal Cancer Participants Who Have Achieved Disease Control Following First-Line Chemotherapy
Tijdsspanne: At 12, 24, and 30 weeks postdose
|
Progression-free survival (PFS) was defined as the time from enrollment to the date of the first objective documentation of disease progression or death resulting from any cause, whichever comes first.
Progression was defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) as at least a 20% increase in the sum of diameters of target lesions.
|
At 12, 24, and 30 weeks postdose
|
|
Percentage Rate of Overall Survival Following Use of CS-7017 in Colorectal Cancer Participants Who Have Achieved Disease Control Following First-Line Chemotherapy
Tijdsspanne: At 3, 6, 9, and 12 months postdose
|
Overall survival (OS) was defined as the time from the date of enrollment to the date of death and assessed by Kaplan Meier analysis.
|
At 3, 6, 9, and 12 months postdose
|
|
Best Overall Response and Objective Response Rate Following Use of CS-7017 in Colorectal Cancer Participants Who Have Achieved Disease Control Following First-Line Chemotherapy
Tijdsspanne: From baseline up to disease progression or the development of unacceptable toxicity (whichever occurs first), up to approximately 3 years 3 months
|
The best overall response was defined as the best response (in the order of confirmed complete response [CR], confirmed partial response [PR], unconfirmed CR, unconfirmed PR, stable disease [SD], and progressive disease [PD]) among all overall responses recorded from the start of treatment until the participant withdrew from the study.
If there was no tumor assessment after the first dose of study drug, the best overall response was classified as Inevaluable.
Based on RECIST v1.0, CR was defined as a disappearance of all target lesions, PR was defined as at least a 30% decrease in the sum of diameters of target lesions, and SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD; at least a 20% increase in the sum of diameters of target lesions.
|
From baseline up to disease progression or the development of unacceptable toxicity (whichever occurs first), up to approximately 3 years 3 months
|
|
Duration of Response for Responding Participants Following Use of CS-7017 in Colorectal Cancer Participants Who Have Achieved Disease Control Following First-Line Chemotherapy
Tijdsspanne: From the date of first objective response (confirmed and unconfirmed CR or PR) to date of progressive disease, up to 3 years 3 months
|
Duration of response was defined for participants with confirmed CR or PR and confirmed and unconfirmed CR or PR as the time from the date of the first documentation of objective response (CR or PR) to the date of the first documentation of progressive disease.
Duration of SD was defined for participants whose best response was SD as the time from the randomization date to the date of the first documentation of progressive disease.
Duration of response was estimated using Kaplan Meier methods.
|
From the date of first objective response (confirmed and unconfirmed CR or PR) to date of progressive disease, up to 3 years 3 months
|
|
Number of Participants With Treatment-Emergent Adverse Events Related to Study Drug With an Incidence of ≥5% Following Use of CS-7017 Or Placebo in Colorectal Cancer Participants Who Have Achieved Disease Control Following First-Line Chemotherapy
Tijdsspanne: Baseline up to 30 days after last study dose, up to 3 years 3 months
|
A treatment-emergent adverse event (TEAE) was defined as any untoward, unfavorable, unintended medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment.
An adverse event that occurs more than 30 days after the last dose of study medication is not included as a TEAE unless it is considered related to treatment.
If relationship is missing, the AE is also considered to be related to the drug.
|
Baseline up to 30 days after last study dose, up to 3 years 3 months
|
Medewerkers en onderzoekers
Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.
Sponsor
Studie record data
Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.
Bestudeer belangrijke data
Studie start (Werkelijk)
31 juli 2009
Primaire voltooiing (Werkelijk)
29 oktober 2012
Studie voltooiing (Werkelijk)
29 oktober 2012
Studieregistratiedata
Eerst ingediend
29 september 2009
Eerst ingediend dat voldeed aan de QC-criteria
29 september 2009
Eerst geplaatst (Schatting)
30 september 2009
Updates van studierecords
Laatste update geplaatst (Werkelijk)
5 november 2020
Laatste update ingediend die voldeed aan QC-criteria
3 november 2020
Laatst geverifieerd
1 november 2020
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
- Ziekten van het spijsverteringsstelsel
- Neoplasmata
- Neoplasmata per site
- Gastro-intestinale neoplasmata
- Neoplasmata van het spijsverteringsstelsel
- Gastro-intestinale aandoeningen
- Colon Ziekten
- Darmziekten
- Intestinale neoplasmata
- Rectale ziekten
- Colorectale neoplasmata
- Antineoplastische middelen
- Efatutazon
Andere studie-ID-nummers
- CS7017-A-E201
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
JA
Beschrijving IPD-plan
De-identified individual participant data (IPD) and applicable supporting clinical trial documents may be available upon request at https://vivli.org/.
In cases where clinical trial data and supporting documents are provided pursuant to our company policies and procedures, Daiichi Sankyo will continue to protect the privacy of our clinical trial participants.
Details on data sharing criteria and the procedure for requesting access can be found at this web address: https://vivli.org/ourmember/daiichi-sankyo/
IPD-tijdsbestek voor delen
Studies for which the medicine and indication have received European Union (EU) and United States (US), and/or Japan (JP) marketing approval on or after 01 January 2014 or by the US or EU or JP Health Authorities when regulatory submissions in all regions are not planned and after the primary study results have been accepted for publication.
IPD-toegangscriteria voor delen
Formal request from qualified scientific and medical researchers on IPD and clinical study documents from clinical trials supporting products submitted and licensed in the United States, the European Union and/or Japan from 01 January 2014 and beyond for the purpose of conducting legitimate research.
This must be consistent with the principle of safeguarding study participants' privacy and consistent with provision of informed consent.
IPD delen Ondersteunend informatietype
- LEERPROTOCOOL
- SAP
- MVO
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .